List of Excipients in Branded Drug FLUZONE HIGH DOSE NORTHERN HEMISPHERE

Fluzone High Dose Northern Hemisphere: Excipient Strategy, Patent Position and Commercial Opportunities

Last updated: August 5, 2026

Fluzone High-Dose is Sanofi’s high-antigen influenza vaccine for adults aged 65 years and older. Its commercial value comes from a 60-microgram hemagglutinin dose per influenza strain, a preservative-free presentation, seasonal reformulation, and distribution through retail pharmacies, physicians and institutional providers. The main excipient opportunities are incremental: improving stability, reducing extractables and leachables, optimizing syringe materials, and supporting manufacturing scale rather than creating a conventional generic substitute.

The product has limited conventional small-molecule patent exposure. Its primary barriers are FDA biologics requirements, strain-specific manufacturing, clinical comparability, supply-chain qualification and Sanofi’s established market access.

What is Fluzone High-Dose Northern Hemisphere?

Fluzone High-Dose is an inactivated influenza vaccine manufactured by Sanofi Pasteur. The Northern Hemisphere product is updated for the influenza strains recommended for each season.

Attribute	Fluzone High-Dose
Manufacturer	Sanofi Pasteur, Inc.
Active product	Inactivated influenza vaccine
Target population	Adults 65 years and older
Route	Intramuscular injection
Dose volume	0.7 mL
Antigen content	60 mcg hemagglutinin per strain
Current formulation direction	Trivalent seasonal influenza vaccine
Presentation	Single-dose prefilled syringe and other approved presentations, depending on season
Preservative	No thimerosal in the single-dose presentation
Regulatory pathway	Biologics license application
Market	Northern Hemisphere seasonal influenza vaccination

The high-dose formulation contains four times the antigen per strain used in standard-dose influenza vaccines. The increased antigen load is intended to produce a stronger immune response in older adults, whose immune systems generally respond less robustly to vaccination.[1]

What excipients are used in Fluzone High-Dose?

The formulation uses a conventional buffered isotonic system with manufacturing-process residual controls. The principal excipient and residual categories identified in product labeling include:

Component or category	Functional role
Sodium chloride	Isotonicity adjustment
Sodium phosphate buffer	pH control
Water for injection	Vehicle
Formaldehyde residual	Viral inactivation and manufacturing-process residual
Octylphenol ethoxylate residual	Manufacturing-process surfactant residual
Egg protein residuals	Potential residual from egg-based production
Container-closure materials	Syringe compatibility and product protection

The exact concentration of each inactive ingredient is controlled through the approved manufacturing process and release specifications. The label identifies residual materials separately from functional excipients because some are process-related rather than deliberately added to the final formulation.[2]

Why the excipient profile matters commercially

The formulation has four commercially relevant characteristics:

1. It is liquid and ready to administer.
2. It avoids the need for reconstitution.
3. It uses a preservative-free single-dose format.
4. It is compatible with mass seasonal administration.

These characteristics support pharmacy-based vaccination, reduce preparation steps and lower the operational burden associated with multidose containers.

What formulation patents protect Fluzone High-Dose?

Fluzone High-Dose is unlikely to be protected by a single formulation patent comparable to a small-molecule drug patent. The relevant intellectual-property value is distributed across:

• High-antigen influenza vaccine compositions.
• Strain selection and reassortant virus production.
• Egg-based propagation and purification.
• Inactivation and filtration processes.
• Antigen quantification and potency assays.
• Stability and container-closure systems.
• Prefilled syringe components.
• Manufacturing know-how and quality-control methods.
• Seasonal regulatory submissions and production capacity.

Public product labeling does not establish a current, enforceable patent list for Fluzone High-Dose. Influenza vaccines are biologics and are generally not managed through the FDA Orange Book in the same way as approved small-molecule medicines.[3]

Are there Orange Book patents for Fluzone High-Dose?

Fluzone High-Dose should not be analyzed as an Orange Book-listed small-molecule product. The FDA Orange Book primarily identifies approved drug products and patent or exclusivity information relevant to generic drug applications. Vaccines licensed under a biologics license application are generally evaluated through the biologics framework rather than conventional ANDA substitution rules.[3]

The absence of an Orange Book patent listing does not mean that Sanofi has no enforceable intellectual property. Process patents, manufacturing know-how, trade secrets, regulatory exclusivity and contractual controls may remain commercially important.

When does Fluzone High-Dose lose exclusivity?

The product’s original biologic exclusivity period is not the sole determinant of competitive entry. The first Fluzone High-Dose product was approved in 2009. FDA reference-product exclusivity for a biologic is generally 12 years from first licensure under the Biologics Price Competition and Innovation Act, subject to statutory rules and applicable supplements.[4]

That period does not create an automatic generic-entry date. A competitor still must obtain an independent FDA approval, typically through a full biologics license application or, where legally and scientifically appropriate, a biosimilar pathway.

Seasonal influenza products also receive recurring regulatory protection from technical and commercial complexity. Each season requires strain selection, production, validation, lot release and supply planning. The product is therefore protected by a combination of regulatory execution and manufacturing scale, even after the original exclusivity period has elapsed.

Can a company launch a generic or biosimilar version of Fluzone High-Dose?

A conventional ANDA generic is not the normal pathway for a high-dose influenza vaccine. A competing manufacturer would generally need to pursue one of the following:

Competitive route	Commercial practicality
Full BLA under section 351(a)	Most direct route for a new influenza vaccine
Biosimilar application under section 351(k)	Legally possible in some circumstances, but technically demanding
Alternative licensed influenza vaccine	More practical where the product has a distinct composition or manufacturing platform
Contract-manufactured or co-developed vaccine	Depends on licensed facilities and Sanofi-independent supply
Private-label seasonal vaccine	Requires regulatory authorization and qualified manufacturing

The main barriers are not only antigen concentration. A competitor must demonstrate consistent strain identity, potency, sterility, purity, safety, manufacturing control and seasonal performance. It also must secure egg, antigen, syringe, fill-finish and distribution capacity.

What generic-entry risks exist?

The principal entry risks are:

• A competing high-dose trivalent influenza vaccine.
• An adjuvanted vaccine that achieves stronger uptake in older adults.
• A cell-based or recombinant vaccine with reduced egg-related concerns.
• A pharmacy or payer preference for lower-cost alternatives.
• Government procurement that shifts share toward price.
• A competitor using a differentiated prefilled syringe or longer stability profile.

The risk of automatic pharmacy substitution is lower than for a conventional tablet because vaccine products are selected through immunization programs, payer contracts, prescriber preference and seasonal procurement.

What excipient strategies could create commercial opportunities?

1. Surfactant replacement and residual reduction

Octylphenol ethoxylate is a process-related surfactant residual. A supplier could pursue alternative surfactants or process conditions that reduce residual levels while preserving viral recovery and antigen integrity.

Commercial value would depend on:

• Equivalent or improved antigen yield.
• Lower residual burden.
• Demonstrated compatibility with inactivation and purification.
• Regulatory acceptance of the revised process.
• Scale-up across seasonal strain changes.

This is more likely to be a licensing or process-development opportunity than a stand-alone finished-dose product opportunity.

2. Prefilled syringe compatibility

The 0.7-mL high-dose presentation creates a focused opportunity in syringe and container-closure engineering. Relevant technologies include:

• Low-binding syringe surfaces.
• Reduced silicone oil exposure.
• Elastomer formulations with lower extractables.
• Improved needle-shield materials.
• Better control of tungsten and glass-related particles.
• Automated device inspection.
• More reliable dose delivery at cold-chain temperatures.

A supplier that can demonstrate lower antigen adsorption or improved stability in a high-antigen formulation may have leverage with vaccine manufacturers and contract fill-finish providers.

3. Stability and cold-chain improvement

Influenza vaccines are distributed through seasonal, high-volume networks. Stabilizing the product against temperature excursions can reduce wastage and expand use in pharmacies, clinics and institutional programs.

Potential approaches include:

• Buffer optimization.
• Protein or surfactant stabilization.
• Reduced interfacial stress.
• Improved container closure.
• Secondary packaging with temperature indicators.
• Formulation changes that preserve hemagglutinin potency.

Any change must preserve immunogenicity and comply with annual strain-update requirements.

4. Egg-protein and process-residual control

Egg-based influenza production can create demand for improved purification, residual testing and process control. Opportunities include:

• Higher-sensitivity ovalbumin assays.
• Faster formaldehyde residual testing.
• Improved surfactant-residual analytics.
• Automated lot-release testing.
• Manufacturing methods that reduce egg-protein carryover.

These technologies can be sold across multiple influenza vaccine manufacturers and may have broader commercial value than a product-specific excipient.

5. Alternative production platforms

Cell-based and recombinant influenza vaccines reduce reliance on egg propagation. They may also offer shorter manufacturing timelines and a different impurity profile. However, a platform shift would compete with the established supply economics and regulatory history of egg-based Fluzone products.

The strongest opportunity is not necessarily replacing every excipient. It may be developing a manufacturing platform that provides better yield, faster strain updates or fewer residual concerns.

How does Fluzone High-Dose compare with competing older-adult influenza vaccines?

Product category	Differentiation	Excipient and formulation opportunity
High-dose influenza vaccine	Higher antigen content	Stability, syringe compatibility and antigen recovery
Adjuvanted influenza vaccine	Immune-response enhancement through adjuvant	Adjuvant dispersion, tolerability and container compatibility
Recombinant influenza vaccine	Non-egg antigen production	Protein stabilization and high-concentration delivery
Cell-based influenza vaccine	Cell-culture manufacturing	Residual control and scale-up
Standard-dose vaccine	Lower antigen content and often lower cost	Manufacturing efficiency and distribution economics

Fluzone High-Dose competes on antigen quantity, brand recognition, clinical familiarity and older-adult channel access. Adjuvanted and recombinant products compete through alternative immunogenicity or production claims rather than direct excipient similarity.[1,5]

What is the FDA regulatory status of Fluzone High-Dose?

FDA approved Fluzone High-Dose for adults aged 65 years and older. The product has historically been marketed in quadrivalent form and has transitioned with the broader seasonal move toward trivalent influenza vaccines after the removal of the B/Yamagata component from recommended formulations.[2,6]

Each annual formulation remains subject to FDA strain-selection and manufacturing requirements. The core product platform may remain stable while the antigenic composition changes by season.

Which companies are challenging the Fluzone High-Dose market?

Competition comes from manufacturers with high-dose, adjuvanted, recombinant or cell-based influenza vaccines. Relevant competitors include CSL Seqirus, AstraZeneca and other influenza vaccine manufacturers with products targeting older adults or broader adult populations.

The competitive threat is commercial rather than litigation-driven. Market access depends on:

• Advisory Committee on Immunization Practices recommendations.
• Medicare and payer reimbursement.
• Pharmacy distribution.
• Government and institutional purchasing.
• Product availability before peak vaccination season.
• Comparative physician and pharmacist preference.

No broad Paragraph IV challenge framework applies in the same way as it does for an Orange Book-listed oral drug.

What patent litigation affects Fluzone High-Dose?

There is no established Orange Book-style Paragraph IV litigation profile for Fluzone High-Dose. Potential disputes would more likely involve:

• Manufacturing-process patents.
• Strain construction or reassortment technology.
• Cell-based or recombinant production methods.
• Adjuvant systems.
• Prefilled syringe components.
• Trade-secret misappropriation.
• License rights involving vaccine platforms.

Sanofi’s practical protection is likely strongest where process know-how, facility qualification and seasonal production execution are difficult to replicate.

How strong is the Fluzone High-Dose patent estate?

The patent estate should be rated as moderate for formulation-specific blocking power and strong for manufacturing and execution barriers.

Protection category	Relative strength
Basic buffered liquid formulation	Low
High-antigen influenza composition	Moderate, depending on claim scope and expiration
Seasonal strain composition	Low to moderate because strains change
Manufacturing process	Moderate to strong
Assays and quality control	Moderate
Prefilled syringe and container closure	Moderate
Trade secrets and know-how	Strong operational value
Regulatory and supply position	Strong commercial value

The most defensible assets are likely to be process controls, analytical methods, manufacturing know-how and qualified capacity rather than generic excipient combinations.

What is the revenue exposure for Sanofi?

Sanofi does not generally report Fluzone High-Dose revenue as a standalone public line item. Revenue exposure is embedded within Sanofi’s broader vaccines business and is sensitive to:

• Annual vaccination rates among adults 65 and older.
• Product mix between high-dose, standard-dose and competing vaccines.
• Government and Medicare reimbursement.
• Seasonal severity and public-health messaging.
• Manufacturing yield and supply availability.
• Pricing pressure from competing products.

The high-dose segment is commercially attractive because older adults have high vaccination rates and receive targeted recommendations. It is also exposed to procurement concentration and competition from adjuvanted and recombinant products.

What licensing deals could create value around Fluzone High-Dose?

The most credible licensing targets are platform technologies that can be applied to multiple vaccine products:

• Low-binding syringe and elastomer systems.
• Antigen-stabilizing excipients.
• Surfactant alternatives.
• Rapid residual-testing methods.
• Cold-chain monitoring systems.
• High-throughput fill-finish technologies.
• Cell-based or recombinant influenza manufacturing.
• Analytical assays for potency and aggregation.

A product-specific excipient license would require evidence that the technology improves stability, yield, safety margin or administration reliability without creating new comparability problems.

What geographic opportunities exist for Northern Hemisphere Fluzone High-Dose?

The Northern Hemisphere formulation is relevant to North America, Europe and other markets using Northern Hemisphere strain recommendations. Commercial expansion depends on local licensure, national procurement rules, cold-chain capacity and the proportion of adults aged 65 and older receiving influenza vaccination.

Excipient and packaging technologies have broader geographic potential than the finished vaccine because they can be incorporated into regional manufacturing or licensed to other vaccine producers. The strongest markets are those with:

• Large older populations.
• High public or private influenza-vaccination coverage.
• Established pharmacy vaccination.
• Reimbursement for premium influenza products.
• Reliable refrigerated distribution.

Key Takeaways

• Fluzone High-Dose is a 0.7-mL, high-antigen influenza vaccine for adults aged 65 and older.
• Its formulation uses a buffered isotonic liquid system and a preservative-free single-dose presentation.
• The strongest excipient opportunities involve stability, residual reduction, syringe compatibility and cold-chain performance.
• Conventional Orange Book and Paragraph IV analysis has limited relevance because the product is a biologic vaccine.
• Competitive entry requires a BLA or another appropriate biologics pathway, not a standard ANDA.
• Manufacturing know-how, seasonal execution, qualified facilities and distribution are major barriers.
• The most valuable licensing opportunities are platform technologies applicable to multiple influenza vaccines.
• Sanofi’s product-specific revenue is not separately disclosed in public company reporting.

FAQs About Fluzone High-Dose Excipients and Commercial Strategy

Does Fluzone High-Dose contain thimerosal?

The single-dose presentation is preservative-free and does not use thimerosal as a preservative. Product-specific labeling should be used for the applicable seasonal presentation.[2]

Is Fluzone High-Dose an egg-based vaccine?

Fluzone products have historically used egg-based influenza virus production. Egg-protein residual control and alternative production platforms remain relevant development areas.

Can an excipient supplier patent a replacement for an existing Fluzone High-Dose excipient?

Potentially, if the replacement provides a novel composition, manufacturing process or measurable performance improvement. Patent value would depend on claim scope, enablement, regulatory approval and freedom-to-operate analysis.

Is Fluzone High-Dose interchangeable with an adjuvanted influenza vaccine?

Interchangeability is determined by applicable regulatory and immunization guidance. High-dose and adjuvanted products use different approaches to improve protection in older adults and are not automatically interchangeable as equivalent products.

What is the highest-value commercial opportunity around Fluzone High-Dose?

The strongest opportunities are technologies that improve antigen stability, reduce process residuals, increase manufacturing yield or improve prefilled-syringe performance across multiple seasonal vaccine products.

References

1. Centers for Disease Control and Prevention. (2024). Prevention and control of seasonal influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices, United States, 2024-25 influenza season. U.S. Department of Health and Human Services.

2. Sanofi Pasteur Inc. (2024). Fluzone High-Dose influenza vaccine prescribing information. U.S. Food and Drug Administration.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. U.S. Department of Health and Human Services.

4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.

5. Centers for Disease Control and Prevention. (2024). Types of influenza vaccines. U.S. Department of Health and Human Services.

6. U.S. Food and Drug Administration. (2024). FDA approves and supports updated seasonal influenza vaccines. U.S. Department of Health and Human Services.